SANES

10.812

+2.02%↑

BBVA

19.67

+0.36%↑

BNP

94.28

+1.26%↑

CABK

11.565

+0.96%↑

INGA

26.315

+0.59%↑

SANES

10.812

+2.02%↑

BBVA

19.67

+0.36%↑

BNP

94.28

+1.26%↑

CABK

11.565

+0.96%↑

INGA

26.315

+0.59%↑

SANES

10.812

+2.02%↑

BBVA

19.67

+0.36%↑

BNP

94.28

+1.26%↑

CABK

11.565

+0.96%↑

INGA

26.315

+0.59%↑

SANES

10.812

+2.02%↑

BBVA

19.67

+0.36%↑

BNP

94.28

+1.26%↑

CABK

11.565

+0.96%↑

INGA

26.315

+0.59%↑

SANES

10.812

+2.02%↑

BBVA

19.67

+0.36%↑

BNP

94.28

+1.26%↑

CABK

11.565

+0.96%↑

INGA

26.315

+0.59%↑

Home・Elenco Azioni・Bayer AG

Bayer AG

Aperta

SettoreFinanza

36.02 2.86

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

35.02

Massimo

35.93

Metriche Chiave
By Trading Economics
Entrata	6.5B 2.8B
Vendite	2B 13B
EPS	2.812
Rendimento da dividendi	0.3
Margine di Profitto	20.612
Dipendenti	87,757
EBITDA	2.3B 4.4B

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+42.8% upside

Dividendi
By Dow Jones
Rendimento da dividendi Media del settore	0.30% 4.65%
Utili prossimi	4 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-1.9B 35B
Apertura precedente	33.16
Chiusura precedente	36.02

Notizie sul Sentiment di mercato

By Acuity

29%

71%

57 / 439 Classifica in Finance

Bayer AG Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 giu 2026, 11:21 UTC

I principali Market Mover

Bayer Shares Fall on Renewed Uncertainty Over $7 Billion U.S. Settlement

12 mag 2026, 11:24 UTC

Utili

I principali Market Mover

Bayer Shares Climb After Earnings Beat Expectations

12 mag 2026, 06:10 UTC

Utili

Bayer Net Profit Surges Driven by Growth in Agricultural Division

6 mag 2026, 10:51 UTC

Acquisizioni, Fusioni, Takeovers

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion -- Update

6 mag 2026, 07:01 UTC

Acquisizioni, Fusioni, Takeovers

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion

2 giu 2026, 11:22 UTC

Discorsi di Mercato

Bayer Hit by New Roundup Legal Jitters -- Market Talk

29 mag 2026, 08:15 UTC

Discorsi di Mercato

Utili

Bayer's Key Pharma Products Face Competitive Risk -- Market Talk

29 mag 2026, 07:42 UTC

Discorsi di Mercato

Bayer Can Still Take Hit if Litigation Strategy Fails -- Market Talk

12 mag 2026, 12:05 UTC

Azioni calde

Stocks to Watch: GameStop, Venture Global, Wendy's, Hims & Hers -- WSJ

12 mag 2026, 10:51 UTC

Azioni calde

Stocks to Watch: GameStop, Venture Global, Hims & Hers, GoPro -- WSJ

12 mag 2026, 09:08 UTC

Azioni calde

Stocks to Watch: Venture Global, Hims & Hers, GoPro -- WSJ

12 mag 2026, 05:38 UTC

Utili

Bayer Backs 2026 Outlook Adjusted for Currency

12 mag 2026, 05:36 UTC

Utili

Bayer 1Q Consumer Health Sales Grew 5.3%, Adjusted for Currency, Portfolio Changes

12 mag 2026, 05:36 UTC

Utili

Bayer 1Q Pharma Sales Fell 0.5%, Adjusted for Currency, Portfolio Changes

12 mag 2026, 05:36 UTC

Utili

Bayer 1Q Crop Science Sales Grew 6.8%, Adjusted for Currency, Portfolio Changes

12 mag 2026, 05:35 UTC

Utili

Bayer 1Q Adj EPS EUR2.71

12 mag 2026, 05:34 UTC

Utili

Analysts Saw Bayer 1Q Net Profit From Continuing Operations at EUR1.60B

12 mag 2026, 05:34 UTC

Utili

Analysts Saw Bayer 1Q Ebitda Before Special Items at EUR3.93B

12 mag 2026, 05:34 UTC

Utili

Analysts Saw Bayer 1Q Sales at EUR13.42B

12 mag 2026, 05:34 UTC

Utili

Bayer 1Q Sales Grew 4.1% When Adjusted for Currency, Portfolio Changes

12 mag 2026, 05:33 UTC

Utili

Bayer 1Q EBIT EUR3.53B

12 mag 2026, 05:32 UTC

Utili

Bayer 1Q Ebitda Before Special Items EUR4.45B

12 mag 2026, 05:32 UTC

Utili

Bayer 1Q Net Pft EUR2.76B

12 mag 2026, 05:31 UTC

Utili

Bayer 1Q Sales EUR13.405B

12 mag 2026, 05:31 UTC

Utili

Bayer Backs 2026 View

6 mag 2026, 06:34 UTC

Acquisizioni, Fusioni, Takeovers

Bayer: Perfuse's Lead Program Is Treatment for Glaucoma and Diabetic Retinopathy

6 mag 2026, 06:33 UTC

Acquisizioni, Fusioni, Takeovers

Bayer: Acquisition Aims to Complement Ophthalmology Pipeline

6 mag 2026, 06:33 UTC

Acquisizioni, Fusioni, Takeovers

Bayer: Additional Payments Subject to Development, Regulatory, and Commercial Milestones

6 mag 2026, 06:32 UTC

Acquisizioni, Fusioni, Takeovers

Bayer to Pay $300M Upfront

6 mag 2026, 06:32 UTC

Acquisizioni, Fusioni, Takeovers

Bayer to Buy Perfuse Therapeutics for Up to $2.45B

Confronto tra pari

Modifica del prezzo

Bayer AG Previsione

Obiettivo di Prezzo

By TipRanks

42.8% in crescita

Previsioni per 12 mesi

Media 49.55 EUR 42.8%

Alto 56 EUR

Basso 40 EUR

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Bayer AG - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Bayer AG - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

57 / 439 Classifica in Finanza

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.